Gilead Drug Approval Fuels Interest in CAR-T Space: 3 Stocks to Consider – Zacks.com
WKSU News |
Gilead Drug Approval Fuels Interest in CAR–T Space: 3 Stocks to Consider
Zacks.com Interest in the CAR-T (chimeric antigen receptor T cells) space continues to build up with the FDA giving its nod to the second CAR-T therapy last week. Gilead Sciences's (GILD – Free Report) Yescarta, a cell-based gene therapy, gained approval for the … Gene Therapy Ushers In a New Era in Cancer Treatment The Floodgates are Open: FDA Approves Second Cancer Gene Therapy FDA approves second gene therapy for cancer |
